STOCK TITAN

[NT 10-Q] – Cannabis Bioscience International Holdings, Inc. (CBIH) (CIK 0001411057)

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
NT 10-Q

Cannabis Bioscience International Holdings (CBIH) filed a Notification of Late Filing (Form 12b-25) for its Form 10-Q for the period ended August 31, 2025, citing that the financial information for the quarter could not be analyzed and completed on a timely basis.

The company provided preliminary estimates indicating a smaller loss from operations of approximately $66,000 versus $97,604 a year earlier. Estimated revenue is about $36,000 compared with $178,887, and estimated gross profit is about $28,000 versus $170,525 for the prior-year quarter. Estimated total operating expenses are approximately $94,000, down from $268,129, reflecting substantial decreases in general and administrative expenses, professional fees, share-based compensation, and rent. Estimated net loss is about $42,511, compared with $76,305 in the prior year.

Cannabis Bioscience International Holdings (CBIH) ha presentato una Notifica di deposito tardivo (Modul 12b-25) per il suo Form 10-Q per il periodo terminato il 31 agosto 2025, dichiarando che le informazioni finanziarie per il trimestre non potevano essere analizzate e completate tempestivamente. L'azienda ha fornito stime preliminary indicando una perdita operativa inferiore a circa $66,000 rispetto a $97,604 dell'anno precedente. Le stime di ricavi sono circa $36,000 rispetto a $178,887, e il profitto lordo stimato è di circa $28,000 rispetto a $170,525 del trimestre dell'anno precedente. Le stime delle spese operative totali sono circa $94,000, in calo dai $268,129, riflettendo notevoli diminuzioni delle spese Generali e Amministrative, onorari professionali, compensi basati sulle azioni e affitto. L'utile netto stimato è circa $42,511, rispetto a $76,305 dello scorso anno.

Cannabis Bioscience International Holdings (CBIH) presentó una Notificación de Presentación Tardía (Formulario 12b-25) para su Form 10-Q para el periodo terminado el 31 de agosto de 2025, alegando que la información financiera del trimestre no pudo ser analizada y completada de manera oportuna. La empresa proporcionó estimaciones preliminares que indican una pérdida operativa menor de aproximadamente $66,000 frente a $97,604 del año anterior. Se estima ingresos de aproximadamente $36,000 comparado con $178,887, y se estima utilidad bruta de aproximadamente $28,000 frente a $170,525 del trimestre del año anterior. Se estiman gastos operativos totales aproximadamente $94,000, desde $268,129, reflejando importantes reducciones en gastos generales y administrativos, honorarios profesionales, compensación basada en acciones y alquiler. Se estima pérdida neta de aproximadamente $42,511, frente a $76,305 en el año anterior.

Cannabis Bioscience International Holdings (CBIH)는 2025년 8월 31일 종료 기간의 Form 10-Q에 대해 지연 제출 통지(Form 12b-25)를 제출했으며, 해당 분기의 재무 정보를 시기 적절하게 분석하고 완료할 수 없었다고 밝혔습니다. 회사는 예비 추정치를 제공했으며 분기 손실이 약 $66,000로 더 작아졌으며 전년 동기 $97,604와 비교됩니다. 추정 수익은 약 $36,000로 전년 동기 $178,887과 비교됩니다. 추정 총이익은 약 $28,000으로 전년 분기 $170,525와 비교됩니다. 추정 총영업비용은 약 $94,000으로 전년 $268,129보다 감소했으며 일반 및 관리 비용, 전문 서비스 수수료, 주식 기반 보상, 임대료 등의 상당한 감소를 반영합니다. 추정 순손실은 약 $42,511로 전년 $76,305와 비교됩니다.

Cannabis Bioscience International Holdings (CBIH) a déposé un Avis de dépôt tardif (Formulaire 12b-25) pour son Form 10-Q pour la période se terminant le 31 août 2025, indiquant que les informations financières du trimestre ne pouvaient être analysées et complétées en temps utile. L'entreprise a fourni des estimations préliminaires indiquant une perte opérationnelle plus faible d'environ $66,000 par rapport à $97,604 l'année précédente. Le chiffre d'affaires estimé est d'environ $36,000 contre $178,887, et le bénéfice brut estimé est d'environ $28,000 contre $170,525 pour le trimestre de l'année précédente. Les dépenses opérationnelles totales estimées sont d'environ $94,000, en baisse par rapport à $268,129, reflétant d'importantes réductions des frais généraux et administratifs, des frais professionnels, de la rémunération fondée sur les actions et du loyer. Le résultat net estimé est d'environ $42,511, comparé à $76,305 l'année précédente.

Cannabis Bioscience International Holdings (CBIH) hat eine Benachrichtigung über verspätete Einreichung (Formular 12b-25) für sein Form 10-Q für den Zeitraum bis zum 31. August 2025 eingereicht und erklärt, dass die Finanzinformationen für das Quartal nicht rechtzeitig analysiert und vervollständigt werden konnten. Das Unternehmen gab vorläufige Schätzungen ab, die auf einen geringeren Verlust aus Betrieben von etwa $66,000 im Vergleich zu $97,604 im Vorjahr hindeuten. Geschätzter Umsatz beträgt etwa $36,000 im Vergleich zu $178,887, und geschätzter Bruttogewinn beträgt etwa $28,000 gegenüber $170,525 im Vorjahresquartal. Geschätzte Gesamtbetriebliche Aufwendungen belaufen sich auf ca. $94,000, gegenüber $268,129, was deutliche Einsparungen bei allgemeinen Verwaltungskosten, professionellen Gebühren, aktienbasierter Vergütung und Miete widerspiegelt. Geschätzter Nettobetriebsverlust beträgt etwa $42,511, verglichen mit $76,305 im Vorjahr.

قامت Cannabis Bioscience International Holdings (CBIH) بتقديم إشعار بتأخر التسجيل (النموذج 12b-25) لForm 10-Q لفترة انتهت في 31 أغسطس 2025، مشيرة إلى أن لا يمكن تحليل المعلومات المالية للربع واكتمالها في الوقت المناسب. قدمت الشركة تقديرات أولية تشير إلى انخفاض الخسارة التشغيلية بمقدار حوالي $66,000 مقارنة بـ $97,604 في السنة السابقة. التقدير للإيرادات حوالي $36,000 مقارنة بـ $178,887، والتقدير للربح الإجمالي حوالي $28,000 مقابل $170,525 للربع السابق من السنة. التقدير للإجمالي المصروفات التشغيلية حوالي $94,000، بانخفاض من $268,129، يعكس انخفاضات كبيرة في النفقات العامة والإدارية، الرسوم المهنية، التعويض المستند إلى الأسهم، والإيجار. التقدير للصافي الخسارة حوالي $42,511، مقارنة بـ $76,305 في السنة السابقة.

Cannabis Bioscience International Holdings (CBIH) 已为其截至2025年8月31日止季度的 Form 10-Q 提交了晚提交通知(Form 12b-25),理由是本季度的财务信息无法及时分析和完成。公司提供初步估计,显示运营亏损约为 $66,000,低于上一年度的 $97,604。预计 收入约为 $36,000,相较于上一年同期的 $178,887;预计 毛利约为 $28,000,相较于上一年度季度的 $170,525。预计 总运营开支约为 $94,000,低于 $268,129,反映出一般及管理费用、专业费用、基于股票的报酬和租金的大幅下降。预计 净亏损约为 $42,511,相比于上一年的 $76,305

Positive
  • None.
Negative
  • None.

Insights

Late NT 10-Q with preliminary metrics: lower revenue, narrower loss.

CBIH filed an NT 10-Q, indicating its quarterly financials weren’t finalized in time. The narrative cites difficulty completing analysis, a common administrative delay. The company also shared preliminary figures to frame expected results.

The estimates show a sharp year-over-year revenue decline to $36,000 with gross profit of $28,000, but materially lower operating expenses of $94,000. This yields a smaller estimated net loss of $42,511 versus $76,305.

Actual results depend on the finalized 10-Q. The filing’s preliminary data suggest cost reductions offset part of the revenue drop; the precise impact will be clear once the report is filed.

Cannabis Bioscience International Holdings (CBIH) ha presentato una Notifica di deposito tardivo (Modul 12b-25) per il suo Form 10-Q per il periodo terminato il 31 agosto 2025, dichiarando che le informazioni finanziarie per il trimestre non potevano essere analizzate e completate tempestivamente. L'azienda ha fornito stime preliminary indicando una perdita operativa inferiore a circa $66,000 rispetto a $97,604 dell'anno precedente. Le stime di ricavi sono circa $36,000 rispetto a $178,887, e il profitto lordo stimato è di circa $28,000 rispetto a $170,525 del trimestre dell'anno precedente. Le stime delle spese operative totali sono circa $94,000, in calo dai $268,129, riflettendo notevoli diminuzioni delle spese Generali e Amministrative, onorari professionali, compensi basati sulle azioni e affitto. L'utile netto stimato è circa $42,511, rispetto a $76,305 dello scorso anno.

Cannabis Bioscience International Holdings (CBIH) presentó una Notificación de Presentación Tardía (Formulario 12b-25) para su Form 10-Q para el periodo terminado el 31 de agosto de 2025, alegando que la información financiera del trimestre no pudo ser analizada y completada de manera oportuna. La empresa proporcionó estimaciones preliminares que indican una pérdida operativa menor de aproximadamente $66,000 frente a $97,604 del año anterior. Se estima ingresos de aproximadamente $36,000 comparado con $178,887, y se estima utilidad bruta de aproximadamente $28,000 frente a $170,525 del trimestre del año anterior. Se estiman gastos operativos totales aproximadamente $94,000, desde $268,129, reflejando importantes reducciones en gastos generales y administrativos, honorarios profesionales, compensación basada en acciones y alquiler. Se estima pérdida neta de aproximadamente $42,511, frente a $76,305 en el año anterior.

Cannabis Bioscience International Holdings (CBIH)는 2025년 8월 31일 종료 기간의 Form 10-Q에 대해 지연 제출 통지(Form 12b-25)를 제출했으며, 해당 분기의 재무 정보를 시기 적절하게 분석하고 완료할 수 없었다고 밝혔습니다. 회사는 예비 추정치를 제공했으며 분기 손실이 약 $66,000로 더 작아졌으며 전년 동기 $97,604와 비교됩니다. 추정 수익은 약 $36,000로 전년 동기 $178,887과 비교됩니다. 추정 총이익은 약 $28,000으로 전년 분기 $170,525와 비교됩니다. 추정 총영업비용은 약 $94,000으로 전년 $268,129보다 감소했으며 일반 및 관리 비용, 전문 서비스 수수료, 주식 기반 보상, 임대료 등의 상당한 감소를 반영합니다. 추정 순손실은 약 $42,511로 전년 $76,305와 비교됩니다.

Cannabis Bioscience International Holdings (CBIH) a déposé un Avis de dépôt tardif (Formulaire 12b-25) pour son Form 10-Q pour la période se terminant le 31 août 2025, indiquant que les informations financières du trimestre ne pouvaient être analysées et complétées en temps utile. L'entreprise a fourni des estimations préliminaires indiquant une perte opérationnelle plus faible d'environ $66,000 par rapport à $97,604 l'année précédente. Le chiffre d'affaires estimé est d'environ $36,000 contre $178,887, et le bénéfice brut estimé est d'environ $28,000 contre $170,525 pour le trimestre de l'année précédente. Les dépenses opérationnelles totales estimées sont d'environ $94,000, en baisse par rapport à $268,129, reflétant d'importantes réductions des frais généraux et administratifs, des frais professionnels, de la rémunération fondée sur les actions et du loyer. Le résultat net estimé est d'environ $42,511, comparé à $76,305 l'année précédente.

Cannabis Bioscience International Holdings (CBIH) hat eine Benachrichtigung über verspätete Einreichung (Formular 12b-25) für sein Form 10-Q für den Zeitraum bis zum 31. August 2025 eingereicht und erklärt, dass die Finanzinformationen für das Quartal nicht rechtzeitig analysiert und vervollständigt werden konnten. Das Unternehmen gab vorläufige Schätzungen ab, die auf einen geringeren Verlust aus Betrieben von etwa $66,000 im Vergleich zu $97,604 im Vorjahr hindeuten. Geschätzter Umsatz beträgt etwa $36,000 im Vergleich zu $178,887, und geschätzter Bruttogewinn beträgt etwa $28,000 gegenüber $170,525 im Vorjahresquartal. Geschätzte Gesamtbetriebliche Aufwendungen belaufen sich auf ca. $94,000, gegenüber $268,129, was deutliche Einsparungen bei allgemeinen Verwaltungskosten, professionellen Gebühren, aktienbasierter Vergütung und Miete widerspiegelt. Geschätzter Nettobetriebsverlust beträgt etwa $42,511, verglichen mit $76,305 im Vorjahr.

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

 

FORM 12b-25

NOTIFICATION OF LATE FILING

 

SEC File No. 333-146758

 

(Check One)     ☐ Form 10-K       ☐ Form 20-F     ☐ Form 11-K     ☒ Form 10-Q      ☐ Form 10-D     ☐ Form N-CEN      ☐ Form N-CSR

 

For Period Ended: August 31, 2025

 

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

 

For the Transition Period Ended: ________________________

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

 

PART I - REGISTRANT INFORMATION

 

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

Full Name of Registrant

 

6201 Bonhomme Road, Suite 435N

Address of Principal Executive Office (Street and Number)

 

Houston, TX 77036

City, State, Zip Code

 

 

 

 

 

 

 

 

 

 

   

 

 

PART II - RULES 12b-25 (b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

    (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
  (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and
    (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

 

PART III - NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof could not be filed within the prescribed time period.

 

The financial information to be contained in the Registrant's Quarterly Report on Form 10-Q for the year ended August 31, 2025, cannot be analyzed and completed on a timely basis.

 

 

PART IV - OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification:

 

Dante Picazo   214   733-0868
(Name)   (Area Code)   (Telephone No.)

 

(2) Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☒ Yes ☐ No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes No

 

Loss from operations for the three months ended August 31, 2025, is estimated to be approximately $66,000, compared with loss from operations of $97.604 for the three months ended August 31, 2024. Revenues and gross profit for the three months ended August 31, 2025, are estimated to be approximately $36,000 and $28,000, respectively, compared with $178,887 and $170,525, respectively, for the three months ended August 31, 2024. Total operating expenses for the three months ended August 31, 2025, are estimated to be approximately $94,000, compared with $268,129 for the three months ended August 31, 2024. Operating expenses were affected principally by substantial decreases in general and administrative expenses, professional fees, share-based compensation and rent. Net loss for the three months ended August 31, 2025, is expected to be approximately $42,511, compared with $76,305 for the three months ended August 31, 2024.

 

 

 

 

 

 2 

 

 

CANNABIS BIOSCIENCE INTERNATIONAL HOLDINGS, INC.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Date: October 15, 2025   By:

/s/ Dante Picazo                   

Chief Executive Officer

(principal executive officer and

principal accounting officer)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 

 

FAQ

What did CBIH (CBIH) file?

CBIH filed a Form 12b-25 (NT 10-Q), notifying a delay in filing its Quarterly Report for the period ended August 31, 2025.

Why is CBIH’s 10-Q delayed?

The company stated the financial information for the quarter could not be analyzed and completed on a timely basis.

What are CBIH’s estimated Q4 revenue and gross profit?

Estimated revenue is about $36,000 and estimated gross profit is about $28,000 for the three months ended August 31, 2025.

How do CBIH’s operating expenses compare year over year?

Estimated operating expenses are about $94,000 versus $268,129 a year earlier, reflecting substantial decreases across several expense categories.

What is CBIH’s estimated net loss for the quarter?

Estimated net loss is about $42,511, compared with $76,305 for the same quarter last year.

Did CBIH indicate significant changes in results of operations?

The company provided estimates showing lower revenue and expenses, with a narrower net loss versus the prior-year quarter.
Cannabis Bioscience International Holdings Inc

OTC:CBIH

CBIH Rankings

CBIH Latest News

CBIH Latest SEC Filings

CBIH Stock Data

5.47M
4.84B
52.8%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Houston